132 related articles for article (PubMed ID: 23376011)
1. Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Davies L; Pons JF; Whittaker S; Marais R; Springer CJ
Bioorg Med Chem; 2013 Mar; 21(5):1284-304. PubMed ID: 23376011
[TBL] [Abstract][Full Text] [Related]
2. Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.
Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie L; Hedley D; Takle AK; Wilson DM; Pons JF; Coulter T; Kirk R; Cantarino N; Whittaker S; Marais R; Springer CJ
Bioorg Med Chem; 2010 Sep; 18(18):6934-52. PubMed ID: 20667740
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAF
Ali EMH; Abdel-Maksoud MS; Ammar UM; Mersal KI; Ho Yoo K; Jooryeong P; Oh CH
Bioorg Chem; 2021 Jan; 106():104508. PubMed ID: 33280830
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
5. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
Nourry A; Zambon A; Davies L; Niculescu-Duvaz I; Dijkstra HP; Ménard D; Gaulon C; Niculescu-Duvaz D; Suijkerbuijk BM; Friedlos F; Manne HA; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Mar; 53(5):1964-78. PubMed ID: 20148563
[TBL] [Abstract][Full Text] [Related]
6. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
9. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
Dietrich J; Gokhale V; Wang X; Hurley LH; Flynn GA
Bioorg Med Chem; 2010 Jan; 18(1):292-304. PubMed ID: 19962319
[TBL] [Abstract][Full Text] [Related]
10. Discovery of New Imidazo[2,1-
Abdel-Maksoud MS; El-Gamal MI; Lee BS; Gamal El-Din MM; Jeon HR; Kwon D; Ammar UM; Mersal KI; Ali EMH; Lee KT; Yoo KH; Han DK; Lee JK; Kim G; Choi HS; Kwon YJ; Lee KH; Oh CH
J Med Chem; 2021 May; 64(10):6877-6901. PubMed ID: 33999621
[TBL] [Abstract][Full Text] [Related]
11. Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1
Kim J; Choi B; Im D; Jung H; Moon H; Aman W; Hah JM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1314-1320. PubMed ID: 31307243
[TBL] [Abstract][Full Text] [Related]
12. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells.
Ramisetti SR; Pandey MK; Lee SY; Karelia D; Narayan S; Amin S; Sharma AK
Eur J Med Chem; 2018 Jan; 143():1919-1930. PubMed ID: 29133035
[TBL] [Abstract][Full Text] [Related]
16. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors.
Li CY; Li QS; Yan L; Sun XG; Wei R; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Jun; 20(12):3746-55. PubMed ID: 22583669
[TBL] [Abstract][Full Text] [Related]
18. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel family of BRAF(V600E) inhibitors.
Qin J; Xie P; Ventocilla C; Zhou G; Vultur A; Chen Q; Liu Q; Herlyn M; Winkler J; Marmorstein R
J Med Chem; 2012 Jun; 55(11):5220-30. PubMed ID: 22537109
[TBL] [Abstract][Full Text] [Related]
20. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
